April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician

April 17, 2025

FDA Reviews Eylea HD for RVO

The agency has initiated priority review of the anti-VEGF agent as a treatment for macular edema secondary to retinal vein occlusion.

Ophthalmology Management

April 16, 2025

Biocon, Regeneron Reach Agreement on Eylea Biosimilar

The agreement clears the way for Yesafili, an FDA-approved aflibercept biosimilar, to be commercialized in the United States.

Retinal Physician

April 03, 2025

FDA Reaches Decision on Reproxalap

The FDA’s Complete Response Letter recommends an additional trial that focuses on DED symptoms.

Conexiant

August 27, 2024

PCPs Play Important Role in Glaucoma Screening

“Recommendations from trusted primary providers have likely kept millions of individuals from becoming blind.”

Conexiant

February 13, 2025

FDA Approves Extended Label for Avacincaptad Pegol

The new label removes limitations on the duration of dosing.

Conexiant

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management

December 17, 2024

New TED Drug Positioned for Success

A groundbreaking late-stage study highlights the effectiveness of Viridian Therapeutics' novel treatment, veligrotug, for chronic thyroid eye disease, offering hope for more convenient and efficient therapy. Positive results led to a substantial boost in the company's stock price.

Reuters

June 06, 2024

U.S. FDA Halts Biomea's Diabetes Trial

Biomea Fusion announced a clinical hold by the U.S. FDA on its diabetes drug trial due to potential toxic liver disease, causing a 60% drop in its shares.

Reuters